{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:10:54Z","timestamp":1783987854454,"version":"3.55.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"DOI":"10.1186\/s11658-026-00940-w","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T09:52:58Z","timestamp":1778233978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RING finger E3 ubiquitin ligases: novel therapeutic opportunities in melanoma"],"prefix":"10.1186","volume":"31","author":[{"given":"Ji-fang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-tian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"9","key":"940_CR1","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1001\/jamaophthalmol.2018.1813","volume":"136","author":"DB Johnson","year":"2018","unstructured":"Johnson DB, Daniels AB. Continued poor survival in metastatic uveal melanoma: implications for molecular prognostication, surveillance imaging, adjuvant therapy, and clinical trials. JAMA Ophthalmol. 2018;136(9):986\u20138.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"940_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"940_CR3","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/j.jaad.2019.01.009","volume":"80","author":"ML Hawkins","year":"2019","unstructured":"Hawkins ML, Rioth MJ, Eguchi MM, Cockburn M. Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment. J Am Acad Dermatol. 2019;80(6):1640\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"940_CR4","doi-asserted-by":"crossref","unstructured":"Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. ESMO Guidelines Committee Electronic address: clinicalguidelines@esmo.org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2019;30(12):1884\u20131901.","DOI":"10.1093\/annonc\/mdz411"},{"issue":"8","key":"940_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.26641","volume":"7","author":"OJ van Not","year":"2024","unstructured":"van Not OJ, van den Eertwegh AJ, Jalving H, Bloem M, Haanen JB, van Rijn RS, et\u00a0al. Long-term survival in patients with advanced melanoma. JAMA Netw Open. 2024;7(8):e2426641.","journal-title":"JAMA Netw Open"},{"key":"940_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1238086","volume":"14","author":"S Zheng","year":"2023","unstructured":"Zheng S, Yu H, Zheng X, Wu UT, Ming WK, Huang H, et\u00a0al. Analysis and prediction of 5-year survival in patients with cutaneous melanoma: a model-based period analysis. Front Endocrinol (Lausanne). 2023;14:1238086.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"33","key":"940_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202402450","volume":"11","author":"JS Guo","year":"2024","unstructured":"Guo JS, Ma J, Zhao XH, Zhang JF, Liu KL, Li LT, et\u00a0al. DHPS-mediated hypusination regulates METTL3 self-m6A-methylation modification to promote melanoma proliferation and the development of novel inhibitors. Adv Sci (Weinh). 2024;11(33):e2402450.","journal-title":"Adv Sci (Weinh)"},{"key":"940_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107453","volume":"209","author":"XH Zhao","year":"2024","unstructured":"Zhao XH, Ma J, Guo JS, Liu KL, Qin YX, Li LT, et al. Novel deoxyhypusine synthase (DHPS) inhibitors target hypusination-induced vasculogenic mimicry (VM) against malignant melanoma. Pharmacol Res. 2024;209:107453. Epub 2024 Oct 10. Erratum in: Pharmacol Res. 2024 Dec;210:107523.","journal-title":"Pharmacol Res"},{"issue":"6509","key":"940_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/373081a0","volume":"373","author":"M Scheffner","year":"1995","unstructured":"Scheffner M, Nuber U, Huibregtse JM. Protein ubiquitination involving an E1-E2-E3 enzyme ubiquitin thioester cascade. Nature. 1995;373(6509):81\u20133.","journal-title":"Nature"},{"issue":"2","key":"940_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41418-020-00703-w","volume":"28","author":"RB Damgaard","year":"2021","unstructured":"Damgaard RB. The ubiquitin system: from cell signaling to disease biology and new therapeutic opportunities. Cell Death Differ. 2021;28(2):423\u20136.","journal-title":"Cell Death Differ"},{"issue":"1","key":"940_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01162-7","volume":"8","author":"W Wang","year":"2022","unstructured":"Wang W, Shi B, Cong R, Hao M, Peng Y, Yang H, et\u00a0al. RING-finger E3 ligases regulatory network in PI3K\/AKT-mediated glucose metabolism. Cell Death Discov. 2022;8(1):372.","journal-title":"Cell Death Discov"},{"issue":"1","key":"940_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01152-2","volume":"7","author":"C Cai","year":"2022","unstructured":"Cai C, Tang YD, Zhai J, Zheng C. The RING finger protein family in health and disease. Signal Transduct Target Ther. 2022;7(1):300.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"940_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-024-06899-8","volume":"7","author":"BB Cheung","year":"2024","unstructured":"Cheung BB, Mittra R, Murray J, Wang Q, Seneviratne JA, Raipuria M, et\u00a0al. Golgi-localized ring finger protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis. Commun Biol. 2024;7(1):1322.","journal-title":"Commun Biol"},{"issue":"5","key":"940_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10051133","volume":"10","author":"F Soysouvanh","year":"2021","unstructured":"Soysouvanh F, Giuliano S, Habel N, El-Hachem N, Pisibon C, Bertolotto C, et\u00a0al. An update on the role of ubiquitination in melanoma development and therapies. J Clin Med. 2021;10(5):1133.","journal-title":"J Clin Med"},{"issue":"6","key":"940_CR15","doi-asserted-by":"publisher","first-page":"4796","DOI":"10.1074\/jbc.M110.157669","volume":"286","author":"J Shloush","year":"2011","unstructured":"Shloush J, Vlassov JE, Engson I, Duan S, Saridakis V, Dhe-Paganon S, et\u00a0al. Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2. J Biol Chem. 2011;286(6):4796\u2013808.","journal-title":"J Biol Chem"},{"issue":"10","key":"940_CR16","doi-asserted-by":"publisher","first-page":"7146","DOI":"10.1074\/jbc.M110.217059","volume":"287","author":"MA Kappo","year":"2012","unstructured":"Kappo MA, Ab E, Hassem F, Atkinson RA, Faro A, Muleya V, et\u00a0al. Solution structure of RING finger-like domain of retinoblastoma-binding protein-6 (RBBP6) suggests it functions as a U-box. J Biol Chem. 2012;287(10):7146\u201358.","journal-title":"J Biol Chem"},{"key":"940_CR17","doi-asserted-by":"publisher","first-page":"1124334","DOI":"10.3389\/fendo.2023.1124334","volume":"14","author":"S Shao","year":"2023","unstructured":"Shao S, Zhou D, Feng J, Liu Y, Baturuhu, Yin H, et\u00a0al. Regulation of inflammation and immunity in sepsis by E3 ligases. Front Endocrinol (Lausanne). 2023;14:1124334.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"16","key":"940_CR18","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1128\/JVI.78.16.8673-8686.2004","volume":"78","author":"X Wang","year":"2004","unstructured":"Wang X, Lybarger L, Connors R, Harris MR, Hansen TH. Model for the interaction of gammaherpesvirus 68 RING-CH finger protein mK3 with major histocompatibility complex class I and the peptide-loading complex. J Virol. 2004;78(16):8673\u201386.","journal-title":"J Virol"},{"issue":"8","key":"940_CR19","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.4161\/psb.20851","volume":"7","author":"P Guzm\u00e1n","year":"2012","unstructured":"Guzm\u00e1n P. The prolific ATL family of RING-H2 ubiquitin ligases. Plant Signal Behav. 2012;7(8):1014\u201321.","journal-title":"Plant Signal Behav"},{"issue":"1","key":"940_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190969","volume":"13","author":"D Jim\u00e9nez-L\u00f3pez","year":"2018","unstructured":"Jim\u00e9nez-L\u00f3pez D, Aguilar-Henonin L, Gonz\u00e1lez-Prieto JM, Aguilar-Hern\u00e1ndez V, Guzm\u00e1n P. CTLs, a new class of RING-H2 ubiquitin ligases uncovered by YEELL, a motif close to the RING domain that is present across eukaryotes. PLoS ONE. 2018;13(1):e0190969.","journal-title":"PLoS ONE"},{"issue":"1","key":"940_CR21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41467-023-35871-z","volume":"14","author":"XS Wang","year":"2023","unstructured":"Wang XS, Cotton TR, Trevelyan SJ, Richardson LW, Lee WT, Silke J, et\u00a0al. The unifying catalytic mechanism of the RING-between-RING E3 ubiquitin ligase family. Nat Commun. 2023;14(1):168.","journal-title":"Nat Commun"},{"issue":"8","key":"940_CR22","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.15252\/embr.201642641","volume":"17","author":"KK Dove","year":"2016","unstructured":"Dove KK, Stieglitz B, Duncan ED, Rittinger K, Klevit RE. Molecular insights into RBR E3 ligase ubiquitin transfer mechanisms. EMBO Rep. 2016;17(8):1221\u201335.","journal-title":"EMBO Rep"},{"issue":"1","key":"940_CR23","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1038\/s41467-025-58807-1","volume":"16","author":"J Dudley-Fraser","year":"2025","unstructured":"Dudley-Fraser J, Esposito D, McPhie KA, Morley-Williams C, Auchynnikava T, Rittinger K. Identification of RING E3 pseudoligases in the TRIM protein family. Nat Commun. 2025;16(1):3456.","journal-title":"Nat Commun"},{"issue":"2","key":"940_CR24","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.coviro.2012.02.003","volume":"2","author":"MG Gr\u00fctter","year":"2012","unstructured":"Gr\u00fctter MG, Luban J. TRIM5 structure, HIV-1 capsid recognition, and innate immune signaling. Curr Opin Virol. 2012;2(2):142\u201350.","journal-title":"Curr Opin Virol"},{"issue":"4","key":"940_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/ni.2548","volume":"14","author":"WA McEwan","year":"2013","unstructured":"McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol. 2013;14(4):327\u201336.","journal-title":"Nat Immunol"},{"issue":"4","key":"940_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1158\/1541-7786.MCR-19-0529","volume":"18","author":"C Stangl","year":"2020","unstructured":"Stangl C, Post JB, van Roosmalen MJ, Hami N, Verlaan-Klink I, Vos HR, et\u00a0al. Diverse BRAF gene fusions confer resistance to EGFR-targeted therapy via differential modulation of BRAF activity. Mol Cancer Res. 2020;18(4):537\u201348.","journal-title":"Mol Cancer Res"},{"issue":"21","key":"940_CR27","doi-asserted-by":"publisher","first-page":"11890","DOI":"10.1093\/nar\/gkaa828","volume":"48","author":"A Corpet","year":"2020","unstructured":"Corpet A, Kleijwegt C, Roubille S, Juillard F, Jacquet K, Texier P, et\u00a0al. PML nuclear bodies and chromatin dynamics: catch me if you can! Nucleic Acids Res. 2020;48(21):11890\u2013912.","journal-title":"Nucleic Acids Res"},{"key":"940_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.968755","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Cao M, Wang P, Chu S, Li M, Hou P, et\u00a0al. The emerging roles of TRIM21 in coordinating cancer metabolism, immunity and cancer treatment. Front Immunol. 2022;13:968755.","journal-title":"Front Immunol"},{"issue":"1","key":"940_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1138-7","volume":"38","author":"CY Wei","year":"2019","unstructured":"Wei CY, Wang L, Zhu MX, Deng XY, Wang DH, Zhang SM, et\u00a0al. TRIM44 activates the AKT\/mTOR signal pathway to induce melanoma progression by stabilizing TLR4. J Exp Clin Cancer Res. 2019;38(1):137.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"940_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1042\/BJ20061138","volume":"399","author":"JH Hurley","year":"2006","unstructured":"Hurley JH, Lee S, Prag G. Ubiquitin-binding domains. Biochem J. 2006;399(3):361\u201372.","journal-title":"Biochem J"},{"issue":"1","key":"940_CR31","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1038\/s41467-025-61111-7","volume":"16","author":"MS Kloet","year":"2025","unstructured":"Kloet MS, Chatrin C, Mukhopadhyay R, van Tol BD, Smith R, Rotman SA, et\u00a0al. Identification of RNF114 as ADPr-Ub reader through non-hydrolysable ubiquitinated ADP-ribose. Nat Commun. 2025;16(1):6319.","journal-title":"Nat Commun"},{"issue":"36","key":"940_CR32","doi-asserted-by":"publisher","first-page":"eadx7172","DOI":"10.1126\/sciadv.adx7172","volume":"11","author":"J Perrard","year":"2025","unstructured":"Perrard J, Gao K, Ring K, Smith S. Deltex and RING-UIM E3 ligases cooperate to create a ubiquitin-ADP-ribose hybrid mark on tankyrase, promoting its stabilization. Sci Adv. 2025;11(36):eadx7172.","journal-title":"Sci Adv"},{"key":"940_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01751","volume":"10","author":"H Lin","year":"2019","unstructured":"Lin H, Li S, Shu HB. The membrane-associated MARCH E3 ligase family: emerging roles in immune regulation. Front Immunol. 2019;10:1751.","journal-title":"Front Immunol"},{"issue":"21","key":"940_CR34","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020105139","volume":"39","author":"K Chathuranga","year":"2020","unstructured":"Chathuranga K, Kim TH, Lee H, Park JS, Kim JH, Chathuranga WAG, et\u00a0al. Negative regulation of NEMO signaling by the ubiquitin E3 ligase MARCH2. EMBO J. 2020;39(21):e105139.","journal-title":"EMBO J"},{"key":"940_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104813","volume":"214","author":"J Liu","year":"2025","unstructured":"Liu J, Song X, Guo W, Liu W, Xu S, Yang Y, et\u00a0al. Unlock the code of MHC II-enabled cancer immunotherapy. Crit Rev Oncol Hematol. 2025;214:104813.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"940_CR36","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2010.05.002","volume":"32","author":"RI Nurieva","year":"2010","unstructured":"Nurieva RI, Zheng S, Jin W, Chung Y, Zhang Y, Martinez GJ, et\u00a0al. The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. Immunity. 2010;32(5):670\u201380.","journal-title":"Immunity"},{"issue":"4","key":"940_CR37","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1021\/acssynbio.2c00587","volume":"12","author":"DH Siepe","year":"2023","unstructured":"Siepe DH, Picton LK, Garcia KC. Receptor elimination by E3 ubiquitin ligase recruitment (REULR): a targeted protein degradation toolbox. ACS Synth Biol. 2023;12(4):1081\u201393.","journal-title":"ACS Synth Biol"},{"issue":"2","key":"940_CR38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/embr.201338166","volume":"15","author":"JJ Smit","year":"2014","unstructured":"Smit JJ, Sixma TK. RBR E3-ligases at work. EMBO Rep. 2014;15(2):142\u201354.","journal-title":"EMBO Rep"},{"issue":"11","key":"940_CR39","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011338","volume":"4","author":"D Narendra","year":"2012","unstructured":"Narendra D, Walker JE, Youle R. Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism. Cold Spring Harb Perspect Biol. 2012;4(11):a011338.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"11","key":"940_CR40","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nri2413","volume":"8","author":"K Ozato","year":"2008","unstructured":"Ozato K, Shin DM, Chang TH, Morse HC 3rd. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol. 2008;8(11):849\u201360.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"940_CR41","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/emmm.201100160","volume":"3","author":"T Kawai","year":"2011","unstructured":"Kawai T, Akira S. Regulation of innate immune signaling pathways by the tripartite motif (TRIM) family proteins. EMBO Mol Med. 2011;3(9):513\u201327.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"940_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56029-z","volume":"16","author":"K Wei","year":"2025","unstructured":"Wei K, Li R, Zhao X, Xie B, Xie T, Sun Q, et\u00a0al. TRIM28 is an essential regulator of three-dimensional chromatin state underpinning CD8+ T cell activation. Nat Commun. 2025;16(1):750.","journal-title":"Nat Commun"},{"issue":"45","key":"940_CR43","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1038\/onc.2011.625","volume":"31","author":"M Wade","year":"2012","unstructured":"Wade M, Li YC, Matani AS, Braun SM, Milanesi F, Rodewald LW, et\u00a0al. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells. Oncogene. 2012;31(45):4789\u201397.","journal-title":"Oncogene"},{"issue":"17","key":"940_CR44","doi-asserted-by":"publisher","first-page":"14052","DOI":"10.1074\/jbc.M111.303875","volume":"287","author":"M Sczaniecka","year":"2012","unstructured":"Sczaniecka M, Gladstone K, Pettersson S, McLaren L, Huart AS, Wallace M. MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism. J Biol Chem. 2012;287(17):14052\u201368.","journal-title":"J Biol Chem"},{"issue":"1","key":"940_CR45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molmed.2006.11.002","volume":"13","author":"LT Vassilev","year":"2007","unstructured":"Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007;13(1):23\u201331.","journal-title":"Trends Mol Med"},{"issue":"2","key":"940_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13(2):83\u201396.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"940_CR47","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1083\/jcb.201309107","volume":"204","author":"S Yamauchi","year":"2014","unstructured":"Yamauchi S, Hou YY, Guo AK, Hirata H, Nakajima W, Yip AK, et\u00a0al. p53-mediated activation of the mitochondrial protease HtrA2\/Omi prevents cell invasion. J Cell Biol. 2014;204(7):1191\u2013207.","journal-title":"J Cell Biol"},{"issue":"2","key":"940_CR48","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/jid.2011.313","volume":"132","author":"Z Ji","year":"2012","unstructured":"Ji Z, Njauw CN, Taylor M, Neel V, Flaherty KT, Tsao H. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol. 2012;132(2):356\u201364.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"940_CR49","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1042\/BJ20121249","volume":"450","author":"S Pettersson","year":"2013","unstructured":"Pettersson S, Sczaniecka M, McLaren L, Russell F, Gladstone K, Hupp T, et\u00a0al. Non-degradative ubiquitination of the Notch1 receptor by the E3 ligase MDM2 activates the Notch signaling pathway. Biochem J. 2013;450(3):523\u201336.","journal-title":"Biochem J"},{"key":"940_CR50","doi-asserted-by":"crossref","unstructured":"Colaluca IN, Tosoni D, Nuciforo P, Senic-Matuglia F, Galimberti V, Viale G, Pece S, Di Fiore PP. NUMB controls p53 tumour suppressor activity. Nature. 2008;451(7174):76\u201380.","DOI":"10.1038\/nature06412"},{"issue":"Pt 7","key":"940_CR51","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1242\/jcs.068965","volume":"124","author":"Y Sun","year":"2011","unstructured":"Sun Y, Klauzinska M, Lake RJ, Lee JM, Santopietro S, Raafat A, et\u00a0al. Trp53 regulates Notch 4 signaling through Mdm2. J Cell Sci. 2011;124(Pt 7):1067\u201376.","journal-title":"J Cell Sci"},{"issue":"5","key":"940_CR52","first-page":"452","volume":"17","author":"P Rajabi","year":"2012","unstructured":"Rajabi P, Karimian P, Heidarpour M. The relationship between MDM2 expression and tumor thickness and invasion in primary cutaneous malignant melanoma. J Res Med Sci. 2012;17(5):452\u20135.","journal-title":"J Res Med Sci"},{"key":"940_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01389","volume":"10","author":"DH Yu","year":"2020","unstructured":"Yu DH, Xu ZY, Mo S, Yuan L, Cheng XD, Qin JJ. Targeting MDMX for cancer therapy: rationale, strategies, and challenges. Front Oncol. 2020;10:1389.","journal-title":"Front Oncol"},{"issue":"8","key":"940_CR54","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/nm.2863","volume":"18","author":"A Gembarska","year":"2012","unstructured":"Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, et\u00a0al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med. 2012;18(8):1239\u201347.","journal-title":"Nat Med"},{"key":"940_CR55","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1146\/annurev-pathol-012414-040349","volume":"11","author":"O Karni-Schmidt","year":"2016","unstructured":"Karni-Schmidt O, Lokshin M, Prives C. The roles of MDM2 and MDMX in cancer. Annu Rev Pathol. 2016;11:617\u201344.","journal-title":"Annu Rev Pathol"},{"issue":"6","key":"940_CR56","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu Y, Su Z, Tavana O, Gu W. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell. 2024;42(6):946\u201367.","journal-title":"Cancer Cell"},{"issue":"5","key":"940_CR57","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1136\/mp.56.5.280","volume":"56","author":"K Pham","year":"2003","unstructured":"Pham K, Milovanovic T, Barr RJ, Truong T, Holcombe RF. Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features. Mol Pathol MP. 2003;56(5):280\u20135.","journal-title":"Mol Pathol MP"},{"issue":"1","key":"940_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0711-z","volume":"12","author":"CY Wei","year":"2019","unstructured":"Wei CY, Zhu MX, Yang YW, Zhang PF, Yang X, Peng R, et\u00a0al. Downregulation of RNF128 activates Wnt\/\u03b2-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma. J Hematol Oncol. 2019;12(1):21.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"940_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-020-00559-0","volume":"18","author":"T Radaszkiewicz","year":"2020","unstructured":"Radaszkiewicz T, Bryja V. Protease associated domain of RNF43 is not necessary for the suppression of Wnt\/\u03b2-catenin signaling in human cells. Cell Commun Signal. 2020;18(1):91.","journal-title":"Cell Commun Signal"},{"key":"940_CR60","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65759","volume":"10","author":"T Radaszkiewicz","year":"2021","unstructured":"Radaszkiewicz T, Noskov\u00e1 M, G\u00f6m\u00f6ryov\u00e1 K, Vond\u00e1lov\u00e1 Blan\u00e1\u0159ov\u00e1 O, Radaszkiewicz KA, Pickov\u00e1 M, et\u00a0al. RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. Elife. 2021;10:e65759.","journal-title":"Elife"},{"issue":"12","key":"940_CR61","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1158\/2159-8290.CD-15-0493","volume":"5","author":"K Rai","year":"2015","unstructured":"Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, et\u00a0al. Dual roles of RNF2 in melanoma progression. Cancer Discov. 2015;5(12):1314\u201327.","journal-title":"Cancer Discov"},{"issue":"2","key":"940_CR62","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/jcb.23385","volume":"113","author":"V Todorovic","year":"2012","unstructured":"Todorovic V, Rifkin DB. LTBPs, more than just an escort service. J Cell Biochem. 2012;113(2):410\u20138.","journal-title":"J Cell Biochem"},{"issue":"10","key":"940_CR63","doi-asserted-by":"publisher","first-page":"10745","DOI":"10.3390\/cimb46100638","volume":"46","author":"C Chiang","year":"2024","unstructured":"Chiang C, Yap BK. TRIM25, TRIM28 and TRIM59 and their protein partners in cancer signaling crosstalk: potential novel therapeutic targets for cancer. Curr Issues Mol Biol. 2024;46(10):10745\u201361.","journal-title":"Curr Issues Mol Biol"},{"issue":"8","key":"940_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081933","volume":"10","author":"S Mazurek","year":"2021","unstructured":"Mazurek S, Oleksiewicz U, Czerwi\u0144ska P, Wr\u00f3blewska J, Klimczak M, Wiznerowicz M. Disruption of RING and PHD domains of TRIM28 evokes differentiation in human iPSCs. Cells. 2021;10(8):1933.","journal-title":"Cells"},{"issue":"1","key":"940_CR65","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202254944","volume":"24","author":"WA Nyberg","year":"2023","unstructured":"Nyberg WA, Velasquez-Pulgarin DA, He T, Sj\u00f6strand M, Pell\u00e9 L, Covacu R, et\u00a0al. The bromodomain protein TRIM28 controls the balance between growth and invasiveness in melanoma. EMBO Rep. 2023;24(1):e54944.","journal-title":"EMBO Rep"},{"issue":"5","key":"940_CR66","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41418-018-0169-5","volume":"26","author":"L Lionnard","year":"2019","unstructured":"Lionnard L, Duc P, Brennan MS, Kueh AJ, Pal M, Guardia F, et\u00a0al. TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1. Cell Death Differ. 2019;26(5):902\u201317.","journal-title":"Cell Death Differ"},{"issue":"1","key":"940_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-017-0374-4","volume":"24","author":"P Czerwi\u0144ska","year":"2017","unstructured":"Czerwi\u0144ska P, Mazurek S, Wiznerowicz M. The complexity of TRIM28 contribution to cancer. J Biomed Sci. 2017;24(1):63.","journal-title":"J Biomed Sci"},{"issue":"9","key":"940_CR68","doi-asserted-by":"publisher","first-page":"13225","DOI":"10.18632\/aging.203003","volume":"13","author":"J Chen","year":"2021","unstructured":"Chen J, Huang L, Quan J, Xiang D. TRIM14 regulates melanoma malignancy via PTEN\/PI3K\/AKT and STAT3 pathways. Aging (Albany NY). 2021;13(9):13225\u201338.","journal-title":"Aging (Albany NY)"},{"key":"940_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-018-0701-1","volume":"18","author":"Z Jin","year":"2018","unstructured":"Jin Z, Li H, Hong X, Ying G, Lu X, Zhuang L, et\u00a0al. TRIM14 promotes colorectal cancer cell migration and invasion through the SPHK1\/STAT3 pathway. Cancer Cell Int. 2018;18:202.","journal-title":"Cancer Cell Int"},{"issue":"Suppl 2","key":"940_CR70","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","volume":"16","author":"A De Luca","year":"2012","unstructured":"De Luca A, Maiello MR, D\u2019Alessio A, Pergameno M, Normanno N. The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signaling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16(Suppl 2):S17-27.","journal-title":"Expert Opin Ther Targets"},{"issue":"35","key":"940_CR71","doi-asserted-by":"publisher","first-page":"14311","DOI":"10.1074\/jbc.M117.792754","volume":"292","author":"T Dogan","year":"2017","unstructured":"Dogan T, Gnad F, Chan J, Phu L, Young A, Chen MJ, et\u00a0al. Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling pathways to the cell cycle. J Biol Chem. 2017;292(35):14311\u201324.","journal-title":"J Biol Chem"},{"issue":"47","key":"940_CR72","doi-asserted-by":"publisher","first-page":"16058","DOI":"10.1074\/jbc.RA120.014615","volume":"295","author":"V Montagnani","year":"2020","unstructured":"Montagnani V, Maresca L, Apollo A, Pepe S, Carr RM, Fernandez-Zapico ME, et\u00a0al. E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1\/2-ELK1 transcriptional axis. J Biol Chem. 2020;295(47):16058\u201371.","journal-title":"J Biol Chem"},{"issue":"6","key":"940_CR73","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jgg.2016.05.005","volume":"43","author":"L Levin","year":"2016","unstructured":"Levin L, Srour S, Gartner J, Kapitansky O, Qutob N, Dror S, et\u00a0al. Parkin somatic mutations link melanoma and Parkinson\u2019s disease. J Genet Genomics. 2016;43(6):369\u201379.","journal-title":"J Genet Genomics"},{"issue":"33","key":"940_CR74","doi-asserted-by":"publisher","first-page":"53869","DOI":"10.18632\/oncotarget.10861","volume":"7","author":"M Nihal","year":"2016","unstructured":"Nihal M, Wood GS. c-CBL regulates melanoma proliferation, migration, invasion and the FAK-SRC-GRB2 nexus. Oncotarget. 2016;7(33):53869\u201380.","journal-title":"Oncotarget"},{"issue":"43","key":"940_CR75","doi-asserted-by":"publisher","first-page":"eadg7752","DOI":"10.1126\/sciadv.adg7752","volume":"9","author":"P Li","year":"2023","unstructured":"Li P, Zhen Y, Kim C, Liu Z, Hao J, Deng H, et\u00a0al. Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer. Sci Adv. 2023;9(43):eadg7752.","journal-title":"Sci Adv"},{"key":"940_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118061","volume":"299","author":"KL Liu","year":"2025","unstructured":"Liu KL, Dong G, Li LT, Liu YZ, Meng QF, Yan YG, et\u00a0al. In silico design, synthesis and biological evaluation of 2-benzyl-5-(2-methoxybenzyl)-1,3,4-oxadiazole derivates as allosteric deoxyhypusine synthase (DHPS) inhibitors for melanoma treatment. Eur J Med Chem. 2025;299:118061.","journal-title":"Eur J Med Chem"},{"issue":"18","key":"940_CR77","doi-asserted-by":"publisher","first-page":"13356","DOI":"10.1021\/acs.jmedchem.1c00582","volume":"64","author":"KL Liu","year":"2021","unstructured":"Liu KL, Li XY, Wang DP, Xue WH, Qian XH, Li YH, et\u00a0al. Novel allosteric inhibitors of deoxyhypusine synthase against malignant melanoma: design, synthesis, and biological evaluation. J Med Chem. 2021;64(18):13356\u201372.","journal-title":"J Med Chem"},{"key":"940_CR78","doi-asserted-by":"crossref","unstructured":"Aguilar A, Lu J, Liu L, Du D, Bernard D, McEachern D, Przybranowski S, Li X, Luo R, Wen B, Sun D, Wang H, Wen J, Wang G, Zhai Y, Guo M, Yang D, Wang S. Discovery of 4-((3\u2032R,4\u2032S,5\u2032R)-6\u2033-chloro-4\u2032-(3-chloro-2-fluorophenyl)-1\u2032-ethyl-2\u2033-oxodispiro[cyclohexane-1,2\u2032-pyrrolidine-3\u2032,3\u2033-indoline]-5\u2032-carboxamido)bicyclo[2.2.2]octane-1-carboxylic acid (AA-115\/APG-115): a potent and orally active murine double minute 2 (MDM2) inhibitor in clinical development. J Med Chem. 2017;60(7):2819\u20132839.","DOI":"10.1021\/acs.jmedchem.6b01665"},{"issue":"9","key":"940_CR79","doi-asserted-by":"publisher","first-page":"15741","DOI":"10.3390\/ijms150915741","volume":"15","author":"Z Yu","year":"2014","unstructured":"Yu Z, Zhuang C, Wu Y, Guo Z, Li J, Dong G, et\u00a0al. Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors. Int J Mol Sci. 2014;15(9):15741\u201353.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"940_CR80","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1021\/acsmedchemlett.6b00488","volume":"8","author":"AL Pietkiewicz","year":"2017","unstructured":"Pietkiewicz AL, Zhang Y, Rahimi MN, Stramandinoli M, Teusner M, McAlpine SR. RITA mimics: synthesis and mechanistic evaluation of asymmetric linked trithiazoles. ACS Med Chem Lett. 2017;8(4):401\u20136.","journal-title":"ACS Med Chem Lett"},{"issue":"3","key":"940_CR81","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1158\/1535-7163.MCT-14-0710","volume":"14","author":"J Canon","year":"2015","unstructured":"Canon J, Osgood T, Olson SH, Saiki AY, Robertson R, Yu D, et\u00a0al. The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents. Mol Cancer Ther. 2015;14(3):649\u201358.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"940_CR82","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1158\/1535-7163.MCT-24-0306","volume":"24","author":"YK Chutake","year":"2025","unstructured":"Chutake YK, Mayo MF, Dumont N, Filiatrault J, Breitkopf SB, Cho P, et\u00a0al. KT-253, a novel MDM2 degrader and p53 stabilizer, has superior potency and efficacy than MDM2 small-molecule inhibitors. Mol Cancer Ther. 2025;24(4):497\u2013510.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"940_CR83","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13058-021-01406-x","volume":"23","author":"S Pairawan","year":"2021","unstructured":"Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, et\u00a0al. First in class dual MDM2\/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res. 2021;23(1):29.","journal-title":"Breast Cancer Res"},{"issue":"14","key":"940_CR84","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1021\/jm400487c","volume":"56","author":"Q Ding","year":"2013","unstructured":"Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, et\u00a0al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2013;56(14):5979\u201383.","journal-title":"J Med Chem"},{"issue":"5","key":"940_CR85","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/sj.bjc.6605199","volume":"101","author":"JA Canner","year":"2009","unstructured":"Canner JA, Sobo M, Ball S, Hutzen B, DeAngelis S, Willis W, et\u00a0al. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer. 2009;101(5):774\u201381.","journal-title":"Br J Cancer"},{"issue":"9","key":"940_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074741","volume":"8","author":"JA Lehman","year":"2013","unstructured":"Lehman JA, Hauck PM, Gendron JM, Batuello CN, Eitel JA, Albig A, et\u00a0al. Serdemetan antagonizes the Mdm2-HIF1\u03b1 axis leading to decreased levels of glycolytic enzymes. PLoS ONE. 2013;8(9):e74741.","journal-title":"PLoS ONE"},{"issue":"36","key":"940_CR87","doi-asserted-by":"publisher","first-page":"E3445","DOI":"10.1073\/pnas.1303002110","volume":"110","author":"YS Chang","year":"2013","unstructured":"Chang YS, Graves B, Guerlavais V, Tovar C, Packman K, To KH, et\u00a0al. Stapled \u03b1-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A. 2013;110(36):E3445\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"940_CR88","doi-asserted-by":"publisher","first-page":"496","DOI":"10.5306\/wjco.v13.i6.496","volume":"13","author":"VHS da Mota","year":"2022","unstructured":"da Mota VHS, Freire de Melo F, de Brito BB, da Silva FAF, Teixeira KN. Molecular docking of DS-3032B, a mouse double minute 2 enzyme antagonist with potential for oncology treatment development. World J Clin Oncol. 2022;13(6):496\u2013504.","journal-title":"World J Clin Oncol"},{"issue":"20","key":"940_CR89","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-25-0762","volume":"31","author":"EE Dumbrava","year":"2025","unstructured":"Dumbrava EE, Stinchcombe TE, Gounder M, et\u00a0al. Milademetan in advanced solid tumors with MDM2 amplification and wild-type TP53: preclinical and phase II clinical trial results. Clin Cancer Res. 2025;31(20):4255\u201364.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"940_CR90","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.18632\/oncotarget.23409","volume":"9","author":"V Arnhold","year":"2017","unstructured":"Arnhold V, Schmelz K, Proba J, et\u00a0al. Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. Oncotarget. 2017;9(2):2304\u201319.","journal-title":"Oncotarget"},{"issue":"5","key":"940_CR91","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/neuonc\/noac271","volume":"25","author":"X Hao","year":"2023","unstructured":"Hao X, Bahia RK, Cseh O, et\u00a0al. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. Neuro Oncol. 2023;25(5):913\u201326.","journal-title":"Neuro Oncol"},{"issue":"12","key":"940_CR92","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1158\/1535-7163.MCT-23-0783","volume":"23","author":"A Gollner","year":"2024","unstructured":"Gollner A, Rudolph D, Weyer-Czernilofsky U, et\u00a0al. Discovery and characterization of brigimadlin, a novel and highly potent MDM2-p53 antagonist suitable for intermittent dose schedules. Mol Cancer Ther. 2024;23(12):1689\u2013702.","journal-title":"Mol Cancer Ther"},{"issue":"25","key":"940_CR93","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1016\/j.cell.2024.10.015","volume":"187","author":"P Lu","year":"2024","unstructured":"Lu P, Cheng Y, Xue L, Ren X, Xu X, Chen C, et\u00a0al. Selective degradation of multimeric proteins by TRIM21-based molecular glue and PROTAC degraders. Cell. 2024;187(25):7126-7142.e20.","journal-title":"Cell"},{"issue":"4","key":"940_CR94","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41589-018-0010-y","volume":"14","author":"LN Gechijian","year":"2018","unstructured":"Gechijian LN, Buckley DL, Lawlor MA, Reyes JM, Paulk J, Ott CJ, et\u00a0al. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nat Chem Biol. 2018;14(4):405\u201312.","journal-title":"Nat Chem Biol"},{"issue":"720","key":"940_CR95","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg3049","volume":"15","author":"J Li","year":"2023","unstructured":"Li J, Liu J, Zhou Z, Wu R, Chen X, Yu C, et\u00a0al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023;15(720):eadg3049.","journal-title":"Sci Transl Med"},{"issue":"37","key":"940_CR96","doi-asserted-by":"publisher","first-page":"26944","DOI":"10.1074\/jbc.M113.461699","volume":"288","author":"IH Ismail","year":"2013","unstructured":"Ismail IH, McDonald D, Strickfaden H, Xu Z, Hendzel MJ. A small molecule inhibitor of polycomb repressive complex 1 inhibits ubiquitin signaling at DNA double-strand breaks. J Biol Chem. 2013;288(37):26944\u201354.","journal-title":"J Biol Chem"},{"issue":"3","key":"940_CR97","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ptr.2058","volume":"21","author":"MK Roy","year":"2007","unstructured":"Roy MK, Kobori M, Takenaka M, Nakahara K, Shinmoto H, Isobe S, et\u00a0al. Antiproliferative effect on human cancer cell lines after treatment with nimbolide extracted from an edible part of the neem tree (Azadirachta indica). Phytother Res. 2007;21(3):245\u201350.","journal-title":"Phytother Res"},{"issue":"6","key":"940_CR98","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1073\/pnas.0507493103","volume":"103","author":"C Tovar","year":"2006","unstructured":"Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, et\u00a0al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006;103(6):1888\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"940_CR99","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pharmthera.2017.03.013","volume":"178","author":"D Nguyen","year":"2017","unstructured":"Nguyen D, Liao W, Zeng SX, Lu H. Reviving the guardian of the genome: small molecule activators of p53. Pharmacol Ther. 2017;178:92\u2013108.","journal-title":"Pharmacol Ther"},{"key":"940_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.823195","volume":"9","author":"VV Grinkevich","year":"2022","unstructured":"Grinkevich VV, Vema A, Fawkner K, Issaeva N, Andreotti V, Dickinson ER, et\u00a0al. Novel allosteric mechanism of dual p53\/MDM2 and p53\/MDM4 inhibition by a small molecule. Front Mol Biosci. 2022;9:823195.","journal-title":"Front Mol Biosci"},{"issue":"12","key":"940_CR101","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1021\/jm051122a","volume":"49","author":"K Ding","year":"2006","unstructured":"Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S, et\u00a0al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 2006;49(12):3432\u20135.","journal-title":"J Med Chem"},{"issue":"10","key":"940_CR102","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.1021\/acs.jmedchem.5b01767","volume":"59","author":"S Daniele","year":"2016","unstructured":"Daniele S, La Pietra V, Barresi E, Di Maro S, Da Pozzo E, Robello M, et\u00a0al. Lead optimization of 2-phenylindolylglyoxylyldipeptide murine double minute (MDM)2\/translocator protein (TSPO) dual inhibitors for the treatment of gliomas. J Med Chem. 2016;59(10):4526\u201338.","journal-title":"J Med Chem"},{"issue":"5","key":"940_CR103","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1021\/jm1011929","volume":"54","author":"IR Hardcastle","year":"2011","unstructured":"Hardcastle IR, Liu J, Valeur E, Watson A, Ahmed SU, Blackburn TJ, et\u00a0al. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency. J Med Chem. 2011;54(5):1233\u201343.","journal-title":"J Med Chem"},{"issue":"14","key":"940_CR104","doi-asserted-by":"publisher","first-page":"9401","DOI":"10.1021\/acs.jmedchem.3c00623","volume":"66","author":"V Guerlavais","year":"2023","unstructured":"Guerlavais V, Sawyer TK, Carvajal L, Chang YS, Graves B, Ren JG, et\u00a0al. Discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized \u03b1-helical peptide in clinical development. J Med Chem. 2023;66(14):9401\u201317.","journal-title":"J Med Chem"},{"issue":"1","key":"940_CR105","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1158\/1535-7163.MCT-10-0581","volume":"10","author":"H Wang","year":"2011","unstructured":"Wang H, Ma X, Ren S, Buolamwini JK, Yan C. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther. 2011;10(1):69\u201379.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"940_CR106","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1021\/acsmedchemlett.3c00439","volume":"14","author":"JA Boerth","year":"2023","unstructured":"Boerth JA, Chinn AJ, Schimpl M, Bommakanti G, Chan C, Code EL, et\u00a0al. Discovery of a novel benzodiazepine series of Cbl-b inhibitors for the enhancement of antitumor immunity. ACS Med Chem Lett. 2023;14(12):1848\u201356.","journal-title":"ACS Med Chem Lett"},{"issue":"2","key":"940_CR107","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1021\/acs.jmedchem.3c02083","volume":"67","author":"AM Mfuh","year":"2024","unstructured":"Mfuh AM, Boerth JA, Bommakanti G, Chan C, Chinn AJ, Code E, et\u00a0al. Discovery, optimization, and biological evaluation of arylpyridones as Cbl-b inhibitors. J Med Chem. 2024;67(2):1500\u201312.","journal-title":"J Med Chem"},{"issue":"16","key":"940_CR108","doi-asserted-by":"publisher","first-page":"14210","DOI":"10.1021\/acs.jmedchem.4c01034","volume":"67","author":"TR Quinn","year":"2024","unstructured":"Quinn TR, Giblin KA, Thomson C, Boerth JA, Bommakanti G, Braybrooke E, et\u00a0al. Accelerated discovery of carbamate Cbl-b inhibitors using generative AI models and structure-based drug design. J Med Chem. 2024;67(16):14210\u201333.","journal-title":"J Med Chem"},{"issue":"7326","key":"940_CR109","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/nature09542","volume":"468","author":"WW Tsai","year":"2010","unstructured":"Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, et\u00a0al. TRIM24 links a non-canonical histone signature to breast cancer. Nature. 2010;468(7326):927\u201332.","journal-title":"Nature"},{"issue":"4","key":"940_CR110","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1021\/acs.jmedchem.5b00405","volume":"59","author":"WS Palmer","year":"2016","unstructured":"Palmer WS, Poncet-Montange G, Liu G, Petrocchi A, Reyna N, Subramanian G, et\u00a0al. Structure-guided design of IACS-9571, a selective high-affinity dual TRIM24-BRPF1 bromodomain inhibitor. J Med Chem. 2016;59(4):1440\u201354.","journal-title":"J Med Chem"},{"issue":"7","key":"940_CR111","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1111\/febs.14041","volume":"284","author":"J Liu","year":"2017","unstructured":"Liu J, Li F, Bao H, Jiang Y, Zhang S, Ma R, et\u00a0al. The polar warhead of a TRIM24 bromodomain inhibitor rearranges a water-mediated interaction network. FEBS J. 2017;284(7):1082\u201395.","journal-title":"FEBS J"},{"issue":"1","key":"940_CR112","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1158\/0008-5472.CAN-18-2918","volume":"79","author":"J Hines","year":"2019","unstructured":"Hines J, Lartigue S, Dong H, Qian Y, Crews CM. MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53. Cancer Res. 2019;79(1):251\u201362.","journal-title":"Cancer Res"},{"issue":"2","key":"940_CR113","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","volume":"62","author":"Y Li","year":"2019","unstructured":"Li Y, Yang J, Aguilar A, McEachern D, Przybranowski S, Liu L, et\u00a0al. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression. J Med Chem. 2019;62(2):448\u201366.","journal-title":"J Med Chem"},{"issue":"5","key":"940_CR114","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051118","volume":"9","author":"B Dum\u00e9tier","year":"2020","unstructured":"Dum\u00e9tier B, Zadoroznyj A, Dubrez L. IAP-mediated protein ubiquitination in regulating cell signaling. Cells. 2020;9(5):1118.","journal-title":"Cells"},{"issue":"2","key":"940_CR115","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nsmb.2231","volume":"19","author":"H Dou","year":"2012","unstructured":"Dou H, Buetow L, Hock A, Sibbet GJ, Vousden KH, Huang DT. Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl. Nat Struct Mol Biol. 2012;19(2):184\u201392.","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"940_CR116","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181\u2013200.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Cellular & Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-026-00940-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00940-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-026-00940-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:02:45Z","timestamp":1783987365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s11658-026-00940-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["940"],"URL":"https:\/\/doi.org\/10.1186\/s11658-026-00940-w","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"27 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}